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1. Introduction 
Immunotherapy for human cancer has remained in the experimental stage for more than a 
century. This lengthy duration reflects as much the scope of failures in the area as it does the 
continuous and remarkable expansion of understanding of immune responses and host-
tumor interaction. Immunotherapy for human cancer has largely focused on immunization 
with peptides or whole antigens, intact tumor cells, or dendritic cells pulsed with antigenic 
peptides isolated from cancers; adoptive transfer of T-cells or immunomodulatory strategies 
such as the use of blocking antibody to cytotoxic T-lymphocyte antigen-4. 
Currently, cytokines have been described and there is much more knowledge of how the 
immune system functions, in particular, how cellular immune responses are generated and 
how peptides can be presented by class I or II molecules. This knowledge has led to the 
peptide approach to tumor immunotherapy. Dendritic cells have emerged and have been 
shown to play an essential role in generating immune responses in patients with cancer. 
Various other methods have also applied for the generation of cell-free vaccines. In addition, 
there are several methods of measuring cellular immunity—cytotoxic T-lymphocytes, T-cell 
proliferation, flow cytometry, ELISPOT, and major histocompatibility complex class I/class 
II tetramers to follow immune activation. Currently, there are two vaccines approved for 
genitourinary cancers (Table 1) with a few others in late stage clinical trials. This chapter 
reviews the development of vaccine cancer immunotherapy in genitourinary cancers. 
 
Cancer Drug Interaction Status 
Renal Cell 
Carcinoma 
Vitespen Heat shock proteins from 
autologous cells 
Approved by Russia in 
2008, on U.S. fast track for 
approval 
Prostate Sipuleucel-T Dendritic Cells Approved in 2010 
Prostate PROSTVAC Prostate-specific antigen Seeking FDA approval 
Bladder OncoTice Bacille Calmette-Guerin Approved 
Table 1. Approved Genitourinary Cancer Vaccines 
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2. Prostate cancer 
As the most common noncutaneous malignancy to affect men and the second leading cause 
of cancer-related deaths in men in the United States, prostate cancer is expected to afflict 
approximately one in six men during their lifetime (Waeckerle-Men, Allmen, Fopp, et al., 
2009). Prostatectomy and radiation therapy has been successful in approximately 80% of 
patients who are diagnosed to be in the early stages of prostate cancer. If a patient fails these 
early stage therapies or has advanced stages of prostate cancer, he undergoes hormonal 
therapies. Unfortunately, not all hormonal therapy is effective in eliminating malignant 
cells, and eventually all patients reach castration-resistant prostate cancer levels. For these 
patients, there are a limited number of successful treatment options, and all of these 
treatments are considered palliative with a median survival of less than two years 
(Waeckerle-Men, Allmen, Fopp, et al., 2009). The approval of docetaxel by the Food and 
Drug Administration in 2004 was able to extend the life expectancy of these patients by two 
months (Thomas-Kaskel, Zeiser, Jochim, et al., 2006). However, docetaxel is cell-cycle 
specific, which means that it is cytotoxic to all dividing cells and not just tumor cells. 
Patients who take docetaxel are likely to experience neutropenia, anemia, neuropathy, 
alopecia, and nail damage. Docetaxel-based therapy is not a cure as some patients fail 
therapy. Because of this, therapeutic strategies that offer a more favorable toxicity profile 
while providing more effective treatments are needed for the management of disease 
progression. Prostate cancer vaccines have the ability to target tumor-specific antigens while 
leaving healthy cells intact (Vieweg, Dannul, 2005). Currently one vaccine is approved for 
the treatment of prostate cancer, and a second vaccine is in the process of seeking Food and 
Drug Administration approval. 
2.1 Peptides and proteins 
One vaccine approach is to use peptides and proteins with or without adjuvant treatment to 
stimulate T cell activation. Many peptide and protein vaccines focus on human leukocyte 
antigen class I-binding prostate-specific antigens or prostate-specific membrane antigens. 
Often a multi-epitope, broad spectrum approach is used. Prostate-specific antigens are the 
most characterized antigen and thus currently the best antigen for the creation of a prostate 
cancer vaccine. Several trials have demonstrated prostate-specific antigen vaccines as 
producing an immunological response. However, the problem with prostate-specific antigen 
vaccines is that this antigen is a secreted protein so it is expressed on healthy cells as well as 
malignant cells. 
Prostate stem cell antigen is expressed on more than 85% of prostate cancer specimens with 
these expression levels increasing with the higher Gleason scores and androgen 
independence (Thomas-Kaskel, Zeiser, Jochim, et al., 2006). One phase I/II study involving 
12 patients receiving four vaccinations bi-weekly examined the safety of prostate stem cell 
antigen vaccines. No adverse reactions were observed, and six patients achieved stable 
disease, and median survival achieved was 22 months. 
Currently, PROSTVAC is in the final stages of clinical development, seeking Food and Drug 
Administration approval. PROSTVAC uses a prostate-specific antigen in combination with 
two poxviruses and three immune enhancing molecules. One randomized, controlled, and 
blinded (2:1 ratio) phase II trial involving 125 patients with minimally systematic castration-
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resistant metastatic prostate cancer evaluated PROSTVAC for safety, progression free 
survival, and overall survival. No association to progression free survival was found in the 
patients receiving PROSTVAC, yet a strong association was found between overall survival 
and those patients receiving PROSTVAC (Kantoff, Schuetz, Blumenstein, et al., 2010). 
Research supports that peptide and protein vaccines may be a viable option for treating 
castration-resistant prostate cancer.  
2.2 Dendritic cell vaccines 
Dendritic cells have been identified as having a critical role in the induction of antitumor 
response as dendritic cells help present tumor-associated antigens to T lymphocytes. 
Researchers have become interested in dendritic cells because all class I or class II-restricted 
protein antigens must be processed by dendritic cells in order to activate the body’s immune 
response (Banchereau, & Steinman, 1998) and to prime and activate CD4+ and CD8+ cells. 
Dendritic cell vaccines have no significant adverse reactions, and an immune response 
against prostate-specific membrane antigen, prostate-specific antigen, prostatic acid 
phosphatase, and telomerase reverse transcriptase has been found in patients receiving the 
vaccine. More recent dendritic cell vaccine trials have adopted a multi-epitope approach to 
overcome malignant cells from evading the body’s immune system. 
Some vaccines focus on prostatic acid phosphatase antigen, an enzyme produced by the 
prostate that is typically only expressed on normal and malignant prostate cells (McNeel, 
Dunphy, Davies, et al., 2009). Preclinical murine studies using vaccines that target prostatic 
acid phosphatase have demonstrated an immunological response as evidenced by CD8+ 
activation (Johnson, Frye, Chinnasamy, et al., 2007). One phase I/IIa trial using a prostatic 
acid phosphatase vaccine found an increase in prostate-specific antigen doubling time and 
CD4+ and CD8+ proliferation with no evidence of significant adverse events cells (McNeel, 
Dunphy, Davies, et al., 2009). 
The only prostate cancer vaccine currently holding Food and Drug Administration approval 
is sipuleucel-T (Provenge), which utilizes autologous dendritic cells activated with the 
proteins PA2024 and prostatic acid phosphatase-linked granulocyte-macrophage colony 
stimulating factor. One randomized trial of sipuleucel-T studied 225 patients with castration 
resistant prostate cancer. Patients received three intravenous infusions approximately two 
weeks apart, and those who received the sipuleucel-T vaccine versus the placebo 
demonstrated a 33% reduction in the risk of death. Overall toxicity profile was favorable 
and consisted mainly of grade 1 or 2 asthenia, chills, dyspnea, headache, pyrexia, vomiting, 
and tremor (Higano, Schellhammer, Small, 2009). 
Multi-epitope dendritic cell vaccines have been under focus as a feasible approach that may 
generate efficient cellular antitumor response. In a phase I/II trial, six patients received a 
total of six dendritic cell vaccines pulsed with prostate stem cell antigen, prostatic acid 
phosphatase, prostate-specific membrane antigen, and prostate-specific antigen biweekly 
followed by a monthly booster injection. Two patients were removed to the study due to 
conflicting treatments or severe pyelonephritis. In the remaining patients, three showed 
evidence of significant antitumor response. With no side effects, this study demonstrated 
that using a multi-epitope approach on a dendritic cell vaccine can elicit a broad T cell 
response (Waeckerle-Men, Allmen, Fopp, et al., 2009). 
www.intechopen.com
 
Advancements in Tumor Immunotherapy and Cancer Vaccines 24
Another multi-epitope dendritic cell vaccine phase I/II randomized, single center trial 
studied 19 human leukocyte antigen-A2 positive patients. Patients received six vaccinations, 
and an immune response was found in eight of the patients with and improved prostate-
specific antigen doubling time in four of those patients (Feyerabend, Stevanovic, 
Gouttefangeas, et al., 2009). A second dendritic vaccine trial focusing on human leukocyte 
antigen-positive patients used a dendritic cell vaccine in combination with prostate-specific 
antigens, prostate-specific membrane antigen, survivn, and prostein. Eight patients received 
four vaccinations bi-weekly demonstrated evidence of prostate-specific antigen response 
and CD8+ T cell activation against prostein, survivn, and prostate-specific membrane 
antigen with no side effects outside of local skin irritation (Fuessel, Meye, Schmitz, et al., 
2006). Evidence from various research trials suggests that multi-epitope vaccines are a 
promising treatment option for advanced prostate cancer. 
2.3 Viral-based immunotherapy 
Using highly immunogenic viruses to express all of the cytotoxic proteins increases the 
visibility of malignant cells to the immune system, and T cells are able to target cancer-
specific antigens. Finding the most beneficial tumor-associated antigens to target has been 
difficult for the development of effective cancer vaccines. However, by using viruses, tumor-
associated antigen vaccines are able to help the immune system recognize malignant cells, 
which eliminates the need to isolate antigens. Virus-based vaccines deliver recombinant 
DNA in a mutated virus that is designed to contain the target antigen within their genome. 
These mutated virus vaccines have been shown to be more potent in stimulating an immune 
response in comparison to proteins and peptides (Pardoll, 2002). 
In prostate cancer vaccines that utilize viruses for the delivery of treatment, research has 
focused on the use of modified vaccinia Arkara virus. TroVax is a current treatment that 
uses vaccinia Arkara, and it is currently in phase II trials. TroVax uses the human oncofetal 
antigen 5T4, which is expressed in high levels on the placenta and on a wide range of 
cancers (including both renal and prostate) but rarely is expressed in healthy tissues 
(Amato, Drur, Naylor, et al., 2008). A phase 2 trial using TroVax involved 27 patients with 
castration-resistant prostate cancer. Of these 27 patients, 14 were treated with TroVax alone 
and 13 received a combination of TroVax and granulocyte macrophage colony-stimulating 
factor. Of the 24 evaluable patients, all achieved a 5T4-specific antibody response. No grade 
3 or 4 toxicities were observed, and minor incidences of myalgia, bone discomfort, low-
grade temperature elevation, and injection site irritation were experienced by patients. 
TroVax was shown to be effective and safe when administered alone or in combination with 
granulocyte macrophage colony-stimulating factor; however, no additional benefit seemed 
to be achieved through the addition of granulocyte macrophage colony-stimulating factor 
(Amato, Drur, Naylor, et al., 2008).  
One study has found that patients who previously received cancer vaccines may respond for 
longer to docetaxel in comparison to a historical control of patients receiving docetaxel alone 
(Arlen, Gulley, Parker, et al., 2006). An active multi-center trial is evaluating progression-
free survival in 80 patients with metastatic castration-resistant prostate cancer receiving 10 
cycles of docetaxel with or without TroVax (Oxford BioMedica & MedSource). This trial is 
expected to conclude in 2016.  
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More recently in pre-clinical murine models, a vaccine has been developed that destroys 
prostate cancer in by producing antigens that attack the prostate tumor cells. By inserting a 
healthy prostate tissue into a mutated vesicular stomatitis virus, researchers are able to 
stimulate T cells to attack malignant cells. Researchers found that T cells only attacked the 
malignant cells and left the healthy tissue unaffected, and no trace of auto-immune disease 
was found in the mice that received the vaccine. Clinical trials in humans for this approach 
are expected to begin within two years. 
3. Renal cell carcinoma 
Early stage renal cell carcinoma is treated with nephrectomy; however, 20-30% of patients 
continue to develop metastatic lesions (Godley & Taylor, 2001). Once metastatic lesions have 
developed, or if distant metastases are already present in nephrectomized renal cell 
carcinoma patients, patients’ prognosis is poor with a median survival of 7 to 11 months. In 
patients at high risk for progression, adjuvant therapy fails to be effective, and in patients 
with advanced renal cell carcinoma, cytotoxic chemotherapy and radiotherapy are 
ineffective while interleukin-2 or interferon-alpha only elicit minimal responses (10-15% of 
patients) (Amato, 2000, Bukowski, 2001). The low effectiveness and high toxicity profiles 
associated with current therapies for advanced renal cell carcinoma creates the need for 
more effective, yet safer, treatment options. Vaccine development for renal cell carcinoma 
proves to be promising with currently one vaccine obtaining Food and Drug Administration 
approval to date and a few other drugs entering phase II/III trials. Current vaccine 
treatments for renal cell carcinoma focus on heat shock proteins, viral vector-based 
immunotherapy, dendritic cells, and other tumor cells in combination with lysates.  
3.1 Heat shock proteins 
Heat shock proteins are a set of proteins that are expressed when the cells are exposed to 
higher temperatures. The genes that encode heat shock proteins were inadvertently 
identified in fruit flies exposed to high temperatures, but these genes, and the proteins that 
encode them, are present in all cells in all forms of life and in a variety of intracellular 
locations. Heat shock proteins have two properties of interest. First, they chaperone 
peptides, and second, they interact with antigen presenting cells in such a manner that leads 
to the presentation of heat shock protein-chaperoned peptides by the major 
histocompatibility complex class I molecules of antigen presenting cells. This has brought 
researchers to the following conclusions: (1) heat shock proteins chaperoning peptides is an 
essential part of the mechanism through which major histocompatibility complex class I 
molecules are charged, (2) heat shock protein-peptide complexes, rather than intact 
antigens, are responsible for antigens transfer during cross-presentation or cross-priming, 
and (3) heat shock protein-peptide complexes provide a distinct antigenic fingerprint for 
specific cancer tissues, which can be utilized in the development of cancer therapies. Most 
research focuses on GP96 (GRP94) and calreticulin, which are found in the endoplasmic 
reticulum, and the cystolic proteins HSP70 and HSP90. 
Human heat shock protein–peptide complexes purified from tumor cells or reconstituted in 
vitro have shown effectiveness in mediating antigen-specific re-presentation of heat shock 
protein-chaperoned peptides and subsequent stimulation of CD4+ and CD8+ T cells. The 
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first human clinical study with autologous heat shock proteins was conducted by Janetzki et 
al. in 16 patients with advanced malignancies. Each patient received 25μg subcutaneous 
injection of tumor-derived HSPPC-96 (vitespen) once weekly for four weeks (Janetzki, Palla, 
Rosenhauer, et al., 2000). Blood samples recovered from patients revealed the CD8+ 
restrictor response against autologous tumor in six out of 12 patients whose responses could 
be tested. Post-vaccination stabilization of disease for three to seven months was observed 
in four patients. One patient with hepatocellular carcinoma was observed to have necrosis of 
over 50% of the tumor coincident with vaccination. Interestingly, this patient had 
synchronous liver metastasis of a different primary tumor that did not respond to the 
vaccine prepared from her primary liver tumor. No evidence of significant toxicity 
associated with heat shock protein vaccine administration was observed in any patient in 
the study. The authors concluded there were signs of clinical responses and showed that a 
T-cell reaction could be generated in a fraction of patients.  
A phase I study evaluated renal cell carcinoma patients treated with vitespen (Amato, 
Murray, Wood, et al., 1999). Patients received 2.5 μg, 25 μg, or 100 μg dose of autologous 
tumor-derived GP96 vaccine weekly for four weeks with a follow up dose at 12 or 20 
weeks if the tumors showed stabilization or regression. Of the 16 patients in the 25 μg 
cohort, one patient achieved complete response, three patients achieved partial response, 
and three patients achieved prolonged stabilization of disease (≥52 weeks). A second 
phase II study confirmed the results (Assikis, Dallani, Pagliaro, et al., 2003). Sixty 
metastatic renal cell cancer patients received 25 μg of HSPPC-96 weekly for four weeks 
and then biweekly until progression. A median of 18 weeks for progression free survival 
in combination with no serious adverse events observed makes HSPPC-96 a promising 
agent for disease stability. 
Another study evaluated time to progression and response rate of autologous vitespen 
administered with or without interleukin 2 in metastatic renal cell carcinoma patients 
(Jonasch, Wood, Tamboli, et al., 2008). Patients received treatments weekly for four weeks 
after surgery followed by two injections biweekly. Of the 60 evaluable patients, two 
demonstrated complete response, two achieved partial response, seven achieved stable 
response, and 33 had disease progression. Two of the patients who were treated with the 
vaccine alone achieved disease stabilization when interleukin 2 was added to the treatment 
regimen. Most patients experienced no discernable benefit from treatment that included 
vitespen; however, use of vitespen in combination with immunoregulatory agents may have 
enhance the efficacy. 
As a result of these findings, a randomized, multicenter phase III trial in renal cell carcinoma 
patients comparing adjuvant vaccination with vitespen was conducted (Wood, Srivastava, 
Bukowski, et al., 2008). After a median follow up of 1.9 years in the intent to treat 
population, recurrence was reported in 37.7% patients in the vaccine group and 39.8% of 
patients in the observation group indicating that recurrence-free survival was not 
significantly improved with the vaccine. Further research is now being done to explore 
whether vitespen improves recurrence-free survival in patients with earlier stage disease. 
Vitespan was approved in 2008 in Russian as an adjuvant therapy to treat renal cell 
carcinoma, and it’s currently on the U.S. Food and Drug Administration’s fast track for 
approval. 
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3.2 Viral vector-based immunotherapy 
Treatment options for advanced metastatic disease, particularly in renal cancer, are highly 
toxic with few clinical benefits. Researchers are focusing on new options that produce 
therapeutic potential while providing a favorable toxicity profile. The use of viral vectors 
has been explored to promote an immune response against target antigens. The primary 
focus of viral vectors is identifying optimal tumor-associated antigens and finding a suitable 
delivery system. Optimal tumor-associated antigens would show minimal expression in 
normal tissues but homogenous, high-level expression on tumors. Additional, optimal 
tumor-associated antigens would not only attack tumors but also actively interfere with 
tumorigenesis.  
MVA-5T4 represents a compelling therapeutic option for certain types of advanced disease. 
More than 700 doses of MVA-5T4 have been given to humans, eliciting potent, sustained 
immune responses in 95% of the more than 200 patients tested (Amato, Karediy, Cao, et al., 
2007). All studies have shown that MVA-5T4 has been safe and well-tolerated, resulting 
only in minor flu-like symptoms and mild reactions at the injection site. Researchers are 
studying the use of MVA-5T4 on metastasized cancers that have proved unresponsive to 
conventional systemic cytotoxic chemotherapy.  
MVA-5T4 has been assessed in conjunction with both high-dose and low-dose interleukin 2 
therapy. In a high-dose study in which patients received MVA-5T4 injections at three-week 
intervals along with 600,000IU/kg interleukin 2 at weeks three, six, nine, and 12 (Kaufman, 
Taback, Sherman, et al., 2009). The results attributed a large number of adverse events to 
high-dose interleukin 2, but only two events (grade I fevers) to MVA-5T4, indicating that the 
regimen is safe and well tolerated in this population of patients. All patients developed 5T4-
specific antibody responses and 13 patients had an increase in 5T4-specific T cell responses. 
The baseline frequency of T regulatory cells was elevated in all patients, those with stable 
disease showed a trend toward increased effector CD8+ T cells and a decrease in T 
regulatory cells. Although vaccination with MVA-5T4 did not improve the objective 
response rates of interleukin 2 therapy but did result in stable disease associated with an 
increase in the ratio of 5T4-specific effector to regulatory T cells in selected patients. 
The low-dose studies further validate the efficacy of MVA-5T4 in combination with low-
dose interleukin 2 and indicate that clear-cell renal cell carcinoma patients appear more 
likely to respond to combination therapy. To validate the efficacy of MVA-5T4 in 
combination with low-dose interleukin 2 in addition to determine the safety, immunological 
and clinical efficacy has been completed (Amato, Shingler, Naylor, et al., 2008). Twenty-five 
patients with metastatic renal cell carcinoma were treated with MVA-5T4 plus low-dose 
interleukin 2. MVA-5T4 was well-tolerated with no serious adverse events attributed to 
vaccination. Of 25 intent-to-treat patients, 21 (84%) mounted 5T4-specific antibody 
responses. Two patients showed a complete response for ≥36 months and one a partial 
response for 12 months. Six patients had disease stabilization from six to 21 months. Median 
progression free survival and overall survival were 3.37 months (range 1.50–24.76) and 12.87 
months (range 1.9–≥24.76), respectively. A statistically significant relationship was detected 
between the magnitude of the 5T4-specific antibody responses and progression free survival 
and overall survival. The authors had concluded that MVA-5T4 in combination with 
interleukin 2 was safe and well-tolerated in all patients. The high frequency of 5T4-specific 
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immune responses and good clinical response rate were encouraging, and support the 
continued testing of MVA-5T4 vaccine in renal cancer patients.  
Another approach in vaccine development for metastatic renal cell carcinoma is MVA-5T4 
in combination with interferon-alpha. In one trial, 28 patients with metastatic renal cell 
carcinoma were treated with MVA-5T4 alone and in combination with interferon-alpha for 
the purpose of determining safety, immunological, and clinical efficacy (Amato, Shingler, 
Goonedwardena, 2009). The vaccine was well-tolerated with no serious adverse events. Of 
the 23 evaluable patients, 22 mounted 5T4-specific antibody and/or cellular responses. One 
patient treated with MVA-5T4 plus interferon-alpha showed a partial response for 12 
months, whereas an additional 14 patients (seven receiving MVA-5T4 plus interferon-alpha 
and seven receiving MVA-5T4 alone) showed periods of disease stabilization ranging from 
1.73 to 9.60 months. Median progression free survival and overall survival for all intent-to-
treat patients was 3.8 months (range 1–11.47) and 12.1 months (range 1–27), respectively. 
MVA-5T4 administered alone or in combination with interferon-alpha was well tolerated in 
all patients. Despite the high frequency of 5T4-specific immune responses, it is not possible 
to conclude that patients were receiving clinical benefit. The immunological results were 
encouraging and the authors warrant further investigation. An open-label phase I/II trial 
administered TroVax alongside interferon-alpha to 11 patients with metastatic renal cell 
carcinoma. Treatment was well tolerated with no serious adverse events, and all patients 
demonstrated 5T4-specific antibody response. Overall median time to progression was 
longer than interferon-alpha when administered alone (Hawkins, Macdermott, Shablak, et 
al., 2009). 
The TroVax renal immunotherapy survival trial (TRIST) was a randomized, placebo-
controlled phase III study that investigated MVA-5T4 added to first-line standard of care to 
evaluate survival of patients with metastatic clear-cell renal cell carcinoma . Seven hundred 
thirty-three patients were recruited, and received a median of eight MVA-5T4 vaccinations 
(Amato, Hawkins, Kaufman, et al., 2010). The standard of care consisted of interleukin 2 in 
24%, interferon-alpha in 51%, and sunitinib in 25% in each treatment arm. Results 
demonstrated that MVA-5T4 was well-tolerated and administered alongside IL-2, IFN-a, 
and sunitinib. No significant differences in overall survival were observed in the two 
treatment arms. Exploratory analyses found patients received significant benefit from this 
vaccine based on certain pretreatment hematologic factors. 
As a result of the TRIST trial, a surrogate for 5T4 response was constructed (immune 
response surrogate). Out of 733 patients, 590 were assessed for immune response. Patients 
with 5T4 antibody response had an associated longer survival within the MVA-5T4 treated 
group. The immune response surrogate was constructed and shown to be a significant 
predictor of treatment benefit. The derivation of the immune response surrogate initiated an 
exploratory, retrospective analysis, which could have important implications for the 
development and use of MVA-5T4 vaccine (Harrop, Shingler, McDonald, et al., 2011). 
3.3 Dendritic cells 
Dendritic cell vaccines are a promising option for cancer vaccine development. Dendritic 
cell vaccines have been evaluated in several clinical studies of patients with advanced renal 
cell carcinoma.  
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In one study by the University of Innsbruck in Austria, isolated dendritic cells and 
administered three consecutive monthly intravenous infusions in seven patients. Results 
demonstrated that the treatment was well-tolerated with moderate fever as the only side 
effect. Immunological response was achieved, but only one patient achieved a partial clinical 
response (Höltl, Rieser, Papesh, et al., 1999, Rieser, Ramoner, Holtl, et al., 2000).  
A second study used a hybrid vaccine of allogeneic dendritic cells and irradiated autologous 
tumor cells in 17 patients with renal cell carcinoma. Patients received the vaccine by 
injection followed by a second injection six weeks later. Patients who demonstrated no 
evidence of disease progression received further booster injections every three months. The 
vaccine was well tolerated with mild to moderate fever and tumor pain as the only adverse 
events observed. After 13 months, four patients had rejected all metastatic tumor lesions, 
and an additional two patients demonstrated a mass reduction of more than 50% (Kugler, 
Stuhler, Walden, et al., 2006). Of interest, the dendritic cell hybrid vaccine induced cytotoxic 
T cells reactive with mucin1 tumor-associated antigen—these results need to be further 
confirmed in larger, randomized trials. 
Tumor-associated antigens can also be applied to the surface of cell-sized microspheres and 
then used as an immunogen. In a phase I/II study, a vaccine consisting of tumor cell 
membrane protein attached to 10 million microspheres was administered to patients 
following palliative resection of metastatic renal cell carcinoma or melanoma (Okazaki, 
Mescher, Curtsinger, et al., 2002). The vaccine was given alone, in combination with 
cyclophosphamide, or in combination with cyclophosphamide and interleukin 2. Two doses 
of vaccine were administered at four-week intervals. Cyclophosphamide was given one 
week before the first vaccine dose in order to decrease T regulatory cells, whereas 
interleukin 2 was administered for one week starting five days after each vaccination in 
order to increase immunogenicity. The first 13 patients in the study included four with 
metastatic renal cell carcinoma. One patient with resected metastatic renal cell carcinoma 
who was treated with the vaccine plus cyclophosphamide and interleukin 2 remained free 
of disease at six months after therapy. 
Another study used a vaccine that contained electrofused allogeneic dendritic cells and 
autologous tumor-derived cells in patients with metastatic renal cell carcinoma. The tumors 
were processed into a single-cell suspension and cryopreserved. Dendritic Cells were 
generated from peripheral blood mononuclear cells isolated from volunteers and cultured 
with granulocyte macrophage colony-stimulating factor, interleukin 4, and tumor necrosis 
factor-alpha. Dendritic cells were then fused to the patient-derived renal cell carcinoma with 
serial electrical pulses. The patients received up to three vaccinations. Twenty-four patients 
underwent this approach. There was no evidence of toxicity related to the vaccine. Two 
patients demonstrated a partial response. Forty-eight percent of the patients demonstrated 
an immunological response with an increase in CD4 and/or CD8+ T-cell expression. The 
authors concluded that this approach was feasible and tolerable. Further development is 
under way in combination with granulocyte macrophage colony-stimulating factor (Avigan, 
Vasir, George, et al., 2007).  
4. Bladder cancer 
Approximately 70% to 80% of patients diagnosed with bladder cancer present with 
superficial, noninvasive malignancies, which can often be cured. Deeply invasive 
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malignancies can sometimes be cured by surgery, radiation therapy, or a combination that 
includes chemotherapy. Patients with invasive tumors confined to bladder muscles after 
cystectomy experience a 75% five-year progression-free survival rate. Patents with deeply 
invasive tumors experience a 30% to 50% 5-year survival rate following cystectomy (Quek, 
Stein, Nichols, et al., 2005). 
4.1 Vaccine approaches 
Less attention has been paid on the development of a bladder cancer vaccine. Most 
treatment for bladder cancer has focused on the use of Bacille Calmette-Guerin following 
resection. Multiple studies have established that treating bladder cancer with a complete 
transurethral resection or fulguration of superficial disease followed by Bacille Calmette-
Guerin prophylaxis significantly reduces recurrence and prolongs disease-free progression 
in comparison to transurethral resection alone (Lamm, 1992). Recurrence is reduced by 7% 
to 65% (Krege, Giani, Meyer, et al., 1996). One study of patients with T1 lesions who were 
treated with Bacille Calmette-Guerin following transurethral resection found that 91% of 
patients were free of tumor recurrence for a mean follow up of 59 months. Sixty-nine 
percent of these remained free of disease after the initial therapy, and another 22% 
underwent an additional transurethral resection followed by Bacille Calmette-Guerin before 
becoming disease free (Cookson & Sarosday, 1992). Bacille Calmette-Guerin following 
transurethral resection has proved to be effective in treating bladder cancer. 
Additional studies are currently underway to determine alternative treatments for patients 
who fail resection and Bacille Calmette-Guerin. In preclinical studies, a conformulation of 
interleukin-12 with chitosan was well tolerated and efficient at curing mice with superficial 
bladder cancer, and an antitumor response was generated in mice receiving this 
conformulation, providing complete protection against intravesical tumor rechallenge 
(Zaharoff, Hoffman, Hooper, et al., 2009).  
Two active studies are expected to near completion within the next two years. One phase II 
study by Iwate Medical University is examining the use of peptides in bladder vaccinations 
following surgery (Iwate Medical University). The investigators are focusing on human 
leukocyte antigen-A*2402 restricted epitope peptides, which when stimulated were found to 
produce a strong interferon-g production. The study will determine feasibility, cytotoxic T 
cell response, CD8+ population, the change in level of regulatory T cells, and overall 
survival. The study is expected to conclude in November 2011. Another active study (phase 
I/II) is focusing on developing a vaccine for metastatic bladder cancer to induce a cellular 
immune response involving both CD4+ and CD8+ T cell populations (Vaxil Therapeutics 
Ltd.). The study will determine the feasibility and safety of administering ImMucin peptide 
combined with human chorionic gonadotropin-colony stimulating factor as well as the 
efficacy of treatment. The study is expected to conclude in September 2012. 
An active study is using CDX-1307, which stimulates an immune response against a protein 
called human chorionic gonadotropin-beta, on patients with muscle invasive bladder cancer 
given before or after cystectomy (Celldex Therapeutics.). This protein, which is made by 
several types of cancers including bladder cancer, has been associated with shorter times to 
development of metastases and reduced survival in bladder cancer. The vaccine in this 
study is expected to cause the immune system to attack human chorionic gonadotropin-
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beta-producing bladder cancer cells to kill or terminate metastasis. This study is expected to 
conclude in October 2017. 
5. Conclusion 
The key to making vaccine therapy a viable option for the treatment of cancer is in 
identifying the subject of patients for which a specific vaccine therapy would be most 
beneficial. Patients who have minimal disease or are in high-risk adjuvant settings are most 
likely to benefit from vaccine therapy as they are least likely to increase tumor suppression 
of the immune system. Patients with advanced disease who are more likely to have 
significant tumor immune suppression will probably benefit more from the use of vaccines 
in combination with other forms of treatment. Additionally, the use of vaccines in 
combination with other forms of immunotherapy may prove to be more effective in treating 
genitourinary cancers. One such form of immunotherapy is sunitinib, which preliminary 
data has shown the potential in decreasing T regulatory cells. 
Cancer vaccines are promising for the treatment of genitourinary cancers, including 
prostate, renal cell carcinoma, and bladder. They offer immunogenic response with a low 
toxicity profile, making them attractive options for patients with advanced stages of cancer. 
In renal cell carcinoma, heat shock protein-based vaccines have demonstrated effectiveness 
in earlier stage renal cell carcinoma patients, but manufacturing the vaccine is time-
consuming. MVA-5T4 has high potential as a viable vaccine therapy for metastatic renal cell 
carcinoma, and it is well tolerated in combination with other therapies. However, more 
information about tumor-associated antigens for renal cell carcinoma is needed before 
taking the next step forward into making viral-based vaccine therapy a viable option. The 
TRIST trial on TroVax helped form an exploratory analysis, which has the potential to make 
significant advances in the development and use of MVA-5T4 vaccines.  
In prostate cancer vaccines, the identification of specific tumor-associated antigens and 
research into related immunogenic treatments is bringing us closer to developing effective 
tumor-specific vaccines that are only cytotoxic to malignant cells. However, further research 
on the molecular and cellular mechanism that regulate antitumor immunity and the 
malignant process will allow for further development of vaccines using more potent 
prostate specific antigens and new protocols to use as vaccines alone or in combination with 
adjuvant therapies.  
Future studies for genitourinary cancer vaccines will need to be refined by optimizing 
patient selection and using tumor-response criteria that are specific to trials of 
immunotherapy. Currently, vitespen is on a fast track for Food and Drug Administration-
approval in the treatment for renal cell carcinoma vaccine with further research being 
conducted in advanced phase clinical trials. One prostate cancer vaccine has already been 
approved by the Food and Drug Administration, and two more prostate cancer vaccines 
(TroVax and PROSTVAC) are in advanced stage trials with PROSTVAC currently seeking 
Food and Drug Administration approval. No vaccine currently is approved for the 
treatment of bladder cancer. Further research needs to be conducted in the way of bladder 
cancer vaccines although bladder cancer is less common and has better prognosis using 
current treatment methods.  
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